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Background: Breast cancer remains a major health problem worldwide, and is becoming increasingly resistant
to traditional drug treatments. For instance, Adriamycin (ADR) is beneficial for the treatment of breast cancer.
However, its wide application often leads to drug resistance in clinic practice, which results in treatment failure.
Gambogenic acid (GNA), a polyprenylated xanthone isolated from the traditional medicine gamboge, has been
reported to effectively inhibit the survival and proliferation of cancer cells. Its effects on ADR resistance have not
yet been reported in breast cancer. In this study, we examined the ability of GNA to modulate ADR resiatance and
the molecular mechanisms underlying this process using a cell based in vitro system.
Methods: An MTT assay was used to evaluate the inhibitory effect of the drugs on the growth of MCF-7 and
MCF-7/ADR cell lines. The effects of drugs on apoptosis were detected using Annexin-V APC/7-AAD double
staining. The expression of apoptosis-related proteins and the proteins in the PTEN/PI3K/AKT pathway were
evaluated by Western blot analysis.
Results: In the MCF-7/ADR cell lines, the IC50 (half maximal inhibitory concentration) of the group that received
combined treatment with GNA and ADR was significantly lower than that in the ADR group, and this value
decreased with an increasing concentration of GNA. In parallel, GNA treatment increased the chemosensitivity of
breast cancer cells to ADR. The cell apoptosis and cell cycle anaysis indicated that the anti-proliferative effect of
GNA is in virtue of increased G0/G1 arrest and potentiated apoptosis. When combined with GNA in MCF-7/ADR
cell lines, the expression levels of the tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on
chromosome ten) and the apoptosis-related proteins caspase-3 and capsese-9 were significantly increased, while
the expression of phosphorylated AKT was decreased.
Conclusions: Our study has indicated a potential role for GNA to increase the chemosensitivity of breast cancer
cells to ADR. This modulatory role was mediated by suppression of the PTEN/PI3K/AKT pathway that led to
apoptosis in MCF-7/ADR cells. This work suggests that GNA may be used as a regulatory agent for treating ADR
resistance in breast cancer patients.
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Breast cancer is one of the most common types of ma-
lignancy in Western countries [1], and its incidence is
increasing in Asian countries, such as China [2, 3]. Des-
pite the improved prognosis of breast cancer patients* Correspondence: wkmys@sohu.com; njhxzh@126.com
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opment of adjuvant therapy, this disease still remains a
major health problem worldwide. Breast cancer is found
mainly in premenopausal women older than 35 years.
The incidence is associated with people’s living habits,-
biological factors, social factors, etc. [4]. Currently,
chemotherapy is one of the most important approaches
in the treatment of breast cancer [5–7]. Adriamycin
(ADR) has been one of the most effective anti-cancer
agents to treat solid tumors [8], including breast cancer,
since its inception [9]; however, the wide application ofdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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and other phenomena in the clinic, leading to treat-
ment failure. Thus, finding a novel drug to reverse re-
sistance to ADR is an important task in breast cancer
chemotherapy [10].
Gambogenic acid (GNA), a dry gum-resin of the Garci-
nia genus, is a xanthonoid anticancer agent found in
Gamboge [11]. It has been reported that GNA can inhibit
cell proliferation by inducing apoptosis and cell cycle
arrest by inactivation of the PTEN/PI3K/AKT signaling
pathway in human tumors [12–15]. Mechanistically, GNA
causes cell cycle arrest during the G0/G1 phase by inhibit-
ing AKT phosphorylation and inducing the apoptosis of
cancer cells via caspase-3. Thus, GNA could effectively
inhibit the survival and proliferation of cancer cells [16].
Interestingly, the PTEN/PI3K/AKT signaling pathway was
reportedly linked to chemotherapy resistance [17, 18]. For
example, the experiment by Sokolosky [19] GSK-3β
activity could result in the altered chemosensitivity of
MCF-7 breast cancer cells to ADR through regulation of
the PI3K/Akt/mTORC1 pathway by phosphorylating sig-
naling molecules such as PTEN and TSC2.
Our previous studies have shown that GNA can
induce apoptosis and inhibit proliferation in MCF-7 and
MDA-MB-231 cell lines [20, 21]. In this study we pro-
vide preliminary evidence that GNA can increase the
chemosensitivity to ADR in human breast cancer cells,
at least in part, by inhibiting the Akt signaling pathway.
Thus, GNA could serve as a modulator in treating ADR
resistance in breast cancer patients.
Methods
Cells and cell culture
Human breast cancer MCF-7 and MCF-7/ADR cell
lines were provided by Dr Jianwei Zhou (the Molecular
Toxicology Laboratory, Nanjing Medical University)
and cultured in Dulbecco’s minimum essential medium
(DMEM, high-glucose) (Hyclone,Logan, USA) supple-
mented with 10 % calf serum (PAA, Ontario, Canada)
at 37 °C with 5 % CO2.
Reagents
Gambogenic acid (GNA) was purchased from Shanghai
Ronghe Medical Technology Co. and was dissolved in
DMSO (Sigma) to make a stock solution. The stock
solution at 100 mg/ml was stored at 4 °C. MTT (3- (4,5-
dimethylthiazol −2-yl)-2,5-diphenyltetra-zolium bromide)
was purchased from Sigma Chemical Company (St. Louis,
MO, USA). All other chemicals used were of the highest
pure commercial grade available.
Cell proliferation assay
Cell proliferation was determined using the MTT assay.
The MCF-7 and MCF-7/ADR cells (5 × 104) were seededonto 96-well plates (Corning, Ithaca, USA). Four hours
later, 10 μl of GNA in DMSO was added to the wells at
various concentrations, and 0.1 % DMSO was used as a
negative control. After 72 h, 50 μl of MTT was added,
and the cells were incubated for another four hours.
After the culture medium was removed, 150 ml of DMSO
was added and the plates were placed on a shaking table
at 150 rpm for 10 min. The optical density (OD) was mea-
sured at 490 nm. The experiments were repeated three
times, and the rate of cell inhibition was calculated using
the following formula: inhibition rate = [1-(OD test/OD
negative control)] × 100 %. The IC50 was calculated using
SPSS 19.0 software.Colony formation and clonogenic assay
The MCF-7 and MCF-7/ADR cells were seeded (1000
cells per well) in 6-well plates and grown at 37 °C in a
5 % CO2 incubator. Next, the cells were treated with
ADR and/or GNA for 24 h, after which the drugs were
washed out and fresh medium was added. After 2 weeks,
colonies were fixed with methanol and stained with
0.1 % crystal violet (Sigma) in PBS for 15 min. Visible
colonies were manually counted. Triplicate wells were
measured in each treatment group.Cell cycle analysis
After treated with ADR alone or in combination with
GNA for 48 h, cells were harvested, washed twice. The
cells used for the cell-cycle analysis were stained with
propidium oxide (100 μg/mL) using the Cycle Test Plus
DNA Reagent Kit (BD Biosciences) and were analyzed
by flow cytometry (FACScan; BD Biosciences) using an
instrument equipped with the CellQuest software pro-
gram (BD Biosciences). The percentages of cells in the
G0–G1, S, and G2–M phases were counted and com-
pared. All of the samples were assayed in triplicate.Apoptosis assay
Cells in the logarithmic growth phase were seeded onto
6-well plates to digest. The next day, pending adherent
cells, seeded cells were added to the appropriate drug-
containing medium accordingly, while the negative
control group did not receive any durgs. After drugs ad-
ministrations for 72 h, we collected cells via 0.25 % tryp-
sin (without EDTA) digestion. The cells were washed
twice with PBS (centrifuge 2000 rpm, 5 min), and we
collected 5 × 105 cells. We added 500 μL of a cell sus-
pension in Binding Buffer, 5 μL of Annexin V-APC, and,
finally, 5 μL of 7-AAD after mixing. At room temperature
and protected from light, the mixture interacted for 5-
15 min. Finally, we assayed for apoptosis using flow cy-
tometry (Ex = 488 nm; Em = 530 nm).
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Cells protein lysates were separated by 10 % SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred to 0.22 μm NC membranes (Sigma) and incubated
with specific antibodies. ECL chromogenic substrate was
used to were quantify bands densitometry (Quantity
One software; Bio-Rad). β-actin antibody (#3741, CST,
USA) was used as a loading control, and anti-caspase-
3(#9915, CST, USA), anti-caspase-9(#9502, CST, USA),
anti-AKT(#9272, CST, USA), anti-p-AKT(#9275, CST,
USA), and anti-PTEN(#9552, CST, USA) (all 1:1000)
were purchased from Cell Signaling Technology, Inc
(CST). The mean ± SD was calculated from three indi-
vidual experiments. The gray scale of protein detection
was analyzed using Gel-Pro32 software.
Evaluation of combined effect and statistical analysis
The interaction between ADR and GNA was calculated
and assessed using a combination index (CI): CI = D1/
D×1 + D2/D×2. D1 and D2 are the concentrations of
ADR and GNA that inhibited cell growth by × % when
they were used in combination, respectively. DX1 and
DX2 are the concentrations of ADR and GNA that re-
sulted in a cell growth inhibition of × %, respectively. A
CI < 1, CI = 1, or CI > 1 indicates synergistic, additive, orFig. 1 Growth inhibitory effect and combination index (CI) of ADR and/or
rates were determined using the MTT assay. MCF-7/ADR cells were treated
MCF-7 cells was used as the control group. b Two cell lines were treated w
with ADR alone were used as a control. c The IC50 values of two cell lines, wh
measured using the MTT assay. According to the experimental results, the mo
GNA2:0.15625 μg/ml, and GNA3:0.3125 μg/ml. d The CI of the two drugs was
effect. The data were presented as the means ± SD of three independent expantagonistic effects, respectively. The data were analyzed
using Calcusyn software (Biosoft, UK).
Statistical evaluation
Values were expressed as the means ± standard devia-
tions. Statistical analysis was performed using Student’s
t-test. Values of p < 0.05 were considered to be statisti-
cally significant.
Results
Modulation of chemosensitivity to ADR in MCF-7/ADR Cells
To study the biologic mechanisms of chemosensitivity to
ADR and find an opportunity to control resistance, we
used an MTT assay to determine the IC50 values of
ADR and GNA alone or in combination in MCF-7 and
MCF-7/ADR cell lines. The results showed that ADR
and GNA inhibited cell growth in a concentration-
dependent manner (Fig. 1a, b). The combination of ADR
and GNA enhanced the growth-inhibitory effect in
MCF-7/ADR cells (cells were treated for 72 h), while the
IC50 decreased from 4.31 μg/ml to 3.34 μg/ml (GNA1:
0.078125 μg/ml), 1.84 μg/ml (GNA2: 0.15625 μg/ml),
and 1.45 μg/ml (GNA3: 0.3125 μg/ml) (Fig. 1d, e).
Nevertheless, this phenomenon of an enhanced inhibitory
ability was not observed in MCF-7 cells (Fig. 1c, e). ThisGNA on MCF-7/ADR and parental MCF-7 cell lines. a Cellular inhibition
with various concentrations of ADR and GNA for 72 h. The group of
ith ADR and various concentrations of GNA for 72 h. The cells treated
ich were treated with ADR and different concentrations of GNA, were
dulatory concentrations were as follows: GNA1:0.078125 μg/ml,
determined using the Chou-Talalay method. CI < 1 indicates a synergistic
eriments. (** P < 0.01 and * P < 0.05)
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had a synergistic anti-tumor effect in MCF-7/ADR cells.
The growth inhibition rates were analyzed using the Chou
and Talalay method. The CI values were < 1, indicating
that the combination of ADR and GNA had a synergistic
growth-inhibitory effect in MCF-7/ADR cells (Fig. 1g).
Similarly, this synergistic effect was not significant in
MCF-7 cells (Fig. 1f).
ADR and GNA alone and in combination inhibit MCF-7/
ADR cell proliferation in vitro
The clonogenic assay was used to study the anti-
proliferative effects of ADR and GNA in MCF-7 and
MCF7/ADR cells. The results showed that ADR in com-
bination with GNA significantly suppressed cell prolifer-
ation in MCF-7/ADR cells, but not in MCF-7 cells. As
shown in Fig. 2, compared with the control cells, the
combination of ADR and GNA in MCF-7/ADR cells re-
sulted in markedly decreased colony formation abilities
(p < 0.05). The colony formation of MCF-7/ADR cells
was significantly inhibited from 107 to 43 and from 75
to 9, respectively, for 10 μg/ml ADR and 20 μg/ml ADR
treatments alone or in combination with GNA.Fig. 2 Effects of ADR and/or GNA on cell growth and proliferation of MCF-
assays were performed to determine the proliferation of the two cell lines.
the means ± SD of three independent experiments. * P < 0.05The combination of ADR and GNA promotes G0/G1 arrest
in MCF-7/ADR cell lines in vitro
To assess whether the anti-proliferative effects of ADR
and GNA on the breast cancer cells were mediated by
inhibiting cell cycle progression, we examined the cell
cycling in MCF-7 and MCF-7/ADR cell lines by flow cy-
tometry after treating the cells with different concentra-
tions of ADR and GNA. The results demonstrated that
the combination of ADR and GNA enhanced a signifi-
cant arrest in the G0/G1-phase in MCF-7/ADR cells,
with an obvious reduction in the number of cells in the
S-phase, and this ability was not observed in MCF-7
cells (Fig. 3). In addition, these data indicate that ADR
and GNA treatment could arrest MCF-7/ADR cells in
the G0/G1-phase of the cell cycle with a concentration-
dependent manner. Taken together, the combination of
ADR and GNA exerts critical effects in MCF-7/ADR cell
lines in vitro by affecting the cell cycle.
GNA increased the ADR-induced apoptotic rate in MCF-7/
ADR cell lines
To further analyze how GNA affects ADR resistance, we
assayed the apoptotic rates in two types of breast cancer7/ADR (b) and parental MCF-7 cell lines (a). Colony-forming growth
The colonies were counted and captured. The data were presented as
Fig. 3 Effects of ADR and GNA on the cell cycle of MCF-7/ADR and parental MCF-7 cell lines in vitro (* P < 0.05). a and b The bar chart represents
the percentage of cells in the G0/G1, S, or G2/M phases, as indicated. The data represent the means ± S.D. from three independent experiments
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results showed that either ADR or GNA alone caused an
increase in the percentage of apoptotic cells compared
with the control group in MCF-7 and MCF-7/ADR cells.
In the MCF-7 cell line, the apoptotic rates were in-
creased from 76.3 % to 85.3 % (10 μg/ml ADR,
0.3125 μg/ml GNA) and from 80.3 % to 88.3 % (20 μg/
ml ADR, 0.3125 μg/ml GNA). In the MCF-7/ADR cell
line, the apoptotic rates were increased from 59.5 % to
71.1 % (10 μg/ml ADR, 0.3125 μg/ml GNA) and from
64.8 % to 75.1 % (20 μg/ml ADR, 0.3125 μg/ml GNA).
By adding GNA, it was revealed that in MCF-7 and
MCF-7/ADR cells, the number of apoptotic tumor cells
was significantly increased in a dose-dependent manner,
as determined using Annexin-V binding, strongly sug-
gesting that GNA treatment caused an increase in apop-
totic cell death by ADR (Fig. 4).
Activation of ADR-induced apoptotic pathways induction
by GNA
We next examined whether the GNA increased cytotox-
icity of ADR was mediated by apoptosis. Our results
showed that by adding 0.3125 μg/ml GNA and 20 μg/mlADR to MCF-7/ADR cell lines for 72 h, the expression
levels of the apoptosis-related proteins caspase-3 and
caspase-9 were increased to varying degrees compared
to the control group (Fig. 5). When GNA and ADR were
combined at the concentrations indicated above, the ex-
pression levels of caspase-3 and caspase-9 were signifi-
cantly increased compared to the ADR group, and the
gray values were higher than the sum of the ADR and
GNA groups. Thus, it was confirmed that GNA could
activate the apoptosis-related proteins caspase-3 and
caspase-9 to induce apoptosis in MCF-7/ADR cell lines,
which modulated the resistance to ADR to some extent.GNA altered the chemosensitivity to ADR via the AKT
signaling pathway
To further clarify how GNA act as a regulatory factor to
modulate drug resistance in MCF-7 and MCF-7/ADR
cells, we adopted the western-blot method to investigate
the Akt phosphorylation status and the expression
changes in PTEN on the upstream PI3K/AKT pathway.
As shown in Fig. 6, cells treated with GNA had enhanced
expression of PTEN, a negative regulator of the PI3K/
Fig. 4 The combined use of ADR and GNA significantly increased ADR-induced apoptosis in MCF-7/ADR cell lines (* P < 0.05). However, the
proportion of increased apoptosis was not obvious in MCF-7 cell lines. The cells were exposed to different concentrations (0, 10, 20 μg/ml) of
ADR with 0.3125 μg/ml GNA for 72 h. a and b The apoptotic rates of cells were detected by flow cytometry. Data represented the mean ± SD
from three independent experiments
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weakened without affecting the expression of total Akt.
The expression of this protein downstream of the Akt sig-
naling pathway was accordingly weakened, which might
lead to the phenomenon of revering drug resistance.
Discussion
Breast cancer is a common type of cancer worldwide, and
its incidence and mortality rates are rising, especially in
premenopausal women [1–4]. ADR is the most effective
anti-cancer agent commonly used in the clinic to treat
various types of cancer, including breast cancer. With the
wide application of ADR, the largest obstacle is its severeFig. 5 MCF-7 and MCF-7/ADR cell lines treated with ADR + GNA showed u
either 0.3125 μg/ml GNA, 20 μg/ml ADR or the combined use of both ADR
caspase-9 and analyzed the expression of caspase proteins by the westernadverse side effects including multidrug resistance [22].
To eliminate this obstacle, we attempted to find a novel
drug to reverse ADR resistance in breast cancer. In this
study, two cell lines, MCF-7/ADR and its parental cell line
MCF-7, were used to investigate the molecular biological
mechanisms of chemotherapy resistance and also verified
the regulatory function of GNA in MCF-7/ADR cells by
MTT assay in vitro. We used an MTT assay to calculate
the corresponding concentrations of the inhibitory rate
after drug treatment. The results showed that the IC50 of
a combination of GNA was significantly lower than that
of the doxorubicin group alone and that the IC50 values
declined with the increasing concentration of GNA inp-regulated expression of caspase-3 and caspase-9. a and b Using
and GNA for 72 h, we used antibodies against caspase-3 and
blot technique. β-actin was used as an internal control. (* P < 0.05)
Fig. 6 The application of ADR and GNA down-regulated the Akt signaling pathway in the MCF-7/ADR cell line. a and b Cells were treated with
20 μg/ml ADR, 0.3125 μg/ml GNA or 20 μg/ml ADR and 0.3125 μg/ml GNA for 72 h. Compared with the ADR group, the expression levels of
p-AKT and PTEN in the ADR + GNA group were significantly increased to varying degrees (P < 0.05)
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modulating the chemosensitivity of breast cancer cells to
ADR was obtained.
Drug resistance is a major obstacle in chemotherapy.
Resistant mechanisms in breast cancer are not entirely
clear [23]. Research on the mechanism of resistance has
been ongoing since the 1960s. In recent years, more
thorough studies of the mechanism of drug resistance in
breast cancer have shown that this process is very com-
plex and requires multiple factors [24]. The PI3K/AKT
pathway is an important signaling pathway that regulates
cell proliferation, and AKT is a key molecule in the
PI3K/AKT pathway [25]. When the extracellular signal
near the cell membrane, receptor and ligand interac-
tions lead to tyrosine kinase activation on the inner
surface of the cell membrane. Further activation of
phosphatidylinositol 3-kinase (PI3K) occurs, leading to
mobilization at the cell membrane so that the substrate
PIP2 (phosphatidylinositol4,5bisphosphate) can be con-
verted to PIP3 (phosphatidylinositol3,4,5triphosphate).
PIP3 is an important lipid second messenger required
to phosphorylate AKT. Then, the phosphorylation of
many proteins by P-AKT may be involved in the
growth and development of cells [26]. PTEN is a pro-
tein phosphatase that acts on tyrosine residues, and is a
major negative regulator of PIP3. Hypermutation of
PTEN occurs in human tumors, including breast can-
cer, black melanoma, endometrial cancer and glioblast-
oma. PTEN has a dual phosphatase activity that regulates
AKT and many downstream signaling proteins [27]. In-
activation of PTEN will lead to the activation of the PI3K/
AKT pathway. Activation of AKT has many biological ac-
tivities, such as, promotion of growth, proliferation, inhib-
ition of apoptosis, enhanced invasion and metastasis,
regulation of endothelial growth and angiogenesis through
the catalysis of a series of protein phosphorylation events
[28, 29].
Several studies have shown that GNA can inhibit pro-
liferation through the induction of apoptosis in lung
cancer cells [12, 30] and can induce mitochondria-dependent apoptosis in human hepatoma HepG2 cells
[31]. Similar results from the A549 lung cancer cell line
have been reported by Cheng H [13] and Yang L [14].
Our previous studies have shown that GNA can induce
apoptosis and inhibit proliferation in the MCF-7 and
MDA-MB-231 cell lines [20, 21]. To further explore the
mechanism of GNA inhibition on proliferation in MCF-
7 and MCF-7/ADR cell lines, we used flow cytometry to
detect the cell cycle progression and apoptosis. The re-
sults demonstrated that a significant arrest in the G0/
G1-phase and an obvious increase in apoptosis after
adding GNA in MCF-7/ADR cells.
Clark’s [32] breast cancer research found that chemo-
therapy drugs can significantly activate PI3K, increase
the levels of activated AKT, and cause cells to be antag-
onistic to chemotherapeutic drugs. Sokolosky’s experi-
ment showed that inhibition of GSK-3β activity could
result in altered chemosensitivity of MCF-7 breast can-
cer cells to ADR through regulation of PI3K/Akt/
mTORC1 pathway activity by phosphorylating signal mol-
ecules such as PTEN and TSC2 [19]. These findings are
consistent with other reports about the Akt signaling
pathway in the role of breast carcinoma. These results
strongly support the hypothesis that inhibition of excessive
activation of Akt plays an important role in the reversal of
chemotherapy resistance. In CNE-1 cells, gambogenic acid
induced apoptosis through the inactivation of the Akt sig-
naling pathway in human nasopharyngeal carcinoma [15].
Based on the experimental results above, we speculate that
GNA reversed drug resistance by regulating the PTEN/
PI3K/AKT signaling pathway, thereby affecting down-
stream target proteins. Here, we used the western-blot
technique to detect three proteins involved in the PTEN/
PI3K/AKT pathway as well as downstream proteins in
MCF-7/ADR cell lines. We found that when combined
with GNA in the MCF-7/ADR cell line, the expression of
PTEN was significantly increased, the expression of phos-
phorylated AKT (i.e., excessive activation of AKT) was de-
creased, and the total AKT content did not change
significantly. Then, we detected the expression levels of
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and found that they were significantly weakened according
to gray-scale. Thus, GNA might act through the PTEN/
PI3K/AKT pathways to inhibit resistant cell proliferation.
Conclusions
This study demonstrated that GNA might inhibit the ac-
tivation of Akt phosphorylation by acting on the nega-
tively regulator of the AKT pathway, PTEN, to enhance
its expression. Subsequently, apoptosis was induced in
breast ADR-resistant cells, demonstrating that the chemo-
sensitivity of breast cancer cells to ADR was modulated.
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